Posted inCardiology Nephrology news
Comprehensive Summary of the FINEARTS-HF Trial Results on Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, and recent heart failure worsening.
